Nabla: Revolutionizing Drug Design with AI and Experiments
Nabla is at the forefront of drug design, leveraging the power of AI and experimental technologies. The company, founded by pioneers in protein language modeling, develops generative models, multiplexed screens, and protein characterization technologies. These tools are applied to design antibodies against some of the most challenging disease targets, from GPCRs to ion channels.
The significance of Nabla's approach lies in its integration of AI-guided design and wet-lab driven measurement. This close collaboration is crucial for designing drugs with superior manufacturability, safety, and efficacy. While AI is a rapidly evolving and impactful technology, the complexity of human biology requires a combination of theoretical and empirical methods. Nabla recognizes this and is working towards filling the gaps in our understanding to create more effective drugs.
In addition to its cutting-edge research and development, Nabla is also partnering with the world's leading pharmaceutical companies. This collaboration aims to maximize the impact of the platform and bring new drugs to patients. The company's team is focused, creative, and holds high scientific standards, based in Cambridge, MA.
Overall, Nabla is making significant contributions to the field of drug design and has the potential to transform the treatment of diseases that have previously eluded us.
